Faes Farma

Faes Farma LT Debt/Equity

The Long-Term Debt to Equity Ratio of Faes Farma (FAE.MC) as of Oct 31, 2026 is 0.50.

LT Debt/Equity

0.50

Last updated:

Long-Term Debt to Equity Ratio of Faes Farma is 2025 0.50 . Long-Term Debt to Equity Ratio of Faes Farma was 2024 0.00 . It decreases by % higher compared to the previous year.

The Faes Farma LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2018
0.00 EUR
Jan 1, 2019
0.00 EUR
Jan 1, 2020
0.00 EUR
Jan 1, 2021
0.00 EUR
Jan 1, 2022
0.01 EUR
Jan 1, 2023
0.00 EUR
Jan 1, 2024
0.00 EUR
Jan 1, 2025
0.50 EUR
The Faes Farma LT Debt/Equity history
YEARLT Debt/EquityYoY
0.50—
0.00—
0.00-100.00%
0.01+81.74%
0.00+15.42%
0.00+280.24%
0.00-62.68%
0.00-98.17%
0.13+1.28 M%
0.00-99.95%
0.02—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Faes Farma Stock analysis

What does Faes Farma do? The history of Faes Farma SA dates back to 1933, when the company was founded in Barcelona, Spain. The founders had a vision to develop innovative products that would contribute to improving the health and well-being of people. Over the following decades, the company grew continuously and established itself as one of the leading players in the pharmaceutical industry. The business model of Faes Farma SA is focused on the development and marketing of products for the healthcare industry. The company relies on research and development to develop innovative solutions for various therapeutic areas. Faes Farma SA distributes its products worldwide through a network of partners and distributors, with a focus on Europe and Latin America. Faes Farma SA operates in three different divisions. The first division is pharmaceuticals, where the company offers products for various areas such as respiratory diseases, allergies, pain, and inflammation. An important part of this segment is the product Bilastine, which is used for the treatment of allergies and is considered an alternative to antihistamines. The second division is animal health. Here, Faes Farma SA offers products for the treatment of pets, including preparations against fleas, ticks, and worms. One of the most well-known products in this area is the Stangest brand, which is considered the leading brand for animal health in Spain. The third division of Faes Farma SA is the business of medical devices and diagnostics. Here, the company offers a wide range of products for various medical applications, including devices for monitoring vital signs and diagnostics for infectious diseases. Overall, Faes Farma SA is a company with a diversified product portfolio that is of interest to both end consumers and healthcare professionals and pet owners. The company has continuously developed and invested in research and development in recent years to expand its product offering and provide innovative solutions for various medical needs. Faes Farma SA is a company that stands out for its commitment to the development of innovative products and its dedication to the health and well-being of humans and animals. With a strong focus on research and development and a wide distribution network, the company has solidified its position in the pharmaceutical industry and will continue to play an important role in the market. Faes Farma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Faes Farma stock

Long-Term Debt to Equity Ratio of Faes Farma is 0.50 in 2025.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Faes Farma since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Faes Farma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Faes Farma

All Key Metrics — Faes Farma